On-column refolding and purification of recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) expressed as inclusion body in Escherichia coli

被引：7
|
作者：
Tan, HD
Dan, GP
Gong, HY
Cao, LJ
机构：
[1] Chinese Acad Sci, Dalian Inst Chem Phys, Dalian 116023, Peoples R China
[2] Yushui Biopharmaceut Co Ltd, Chongqing 200400, Peoples R China
来源：
BIOTECHNOLOGY LETTERS | 2005年 / 27卷 / 16期
关键词：
human interleukin-1 receptor antagonist; inclusion body; on-column refolding;
D O I：
10.1007/s10529-005-8655-5
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) was produced in E. coli as an inclusion body. rHuIL-1ra was purified to Over 98% purity by anion exchange chromatography after on-column refolding. The optimized processes produced more than 2 g pure refolded rHuIL-1ra per 1 l culture, corresponding to a 44% recovery, without an intermediate dialysis step. Refolded rHuIL-1ra had full biological activity with the MTT assay. An intramolecular disulfide linkage in the oxidized recombinant protein was suggested by data from HPLC and non-reducing SDS-PAGE.
引用
收藏
页码：1177 / 1182
页数：6
相关论文
共 50 条
  • [41] Heterogeneous Treatment Effect Of Recombinant Human Interleukin-1 Receptor Antagonist For Human Severe Sepsis
    Meyer, N. J.
    Dunn, T. G.
    Reilly, J. P.
    Palakshappa, J. A.
    Feng, R.
    Christie, J. D.
    Palardy, J. E.
    Opal, S. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [42] Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist
    Chi, EY
    Kendrick, BS
    Carpenter, JF
    Randolph, TW
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (12) : 2735 - 2748
  • [43] BIOLOGICAL PROPERTIES OF RECOMBINANT HUMAN MONOCYTE-DERIVED INTERLEUKIN-1 RECEPTOR ANTAGONIST
    AREND, WP
    WELGUS, HG
    THOMPSON, RC
    EISENBERG, SP
    JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05): : 1694 - 1697
  • [44] HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST - HIGH-YIELD EXPRESSION IN ESCHERICHIA-COLI AND EXAMINATION OF CYSTEINE RESIDUES
    STEINKASSERER, A
    SOLARI, R
    MOTT, HR
    APLIN, RT
    ROBINSON, CC
    WILLIS, AC
    SIM, RB
    FEBS LETTERS, 1992, 310 (01) : 63 - 65
  • [45] Purification and refolding of human beta-secretase 1 (BACE1) expressed from Escherichia coli for structure determination
    Lin, L
    Strand, J
    Tam, A
    Liu, C
    Svenson, K
    Chopra, R
    Bridges, K
    DiBlasio-Smith, E
    Hsiao, C
    Liu, Y
    PROTEIN SCIENCE, 2004, 13 : 222 - 222
  • [46] PURIFICATION AND CHARACTERIZATION OF RECOMBINANT HUMAN INTERLEUKIN-1-BETA PRODUCED IN ESCHERICHIA-COLI
    KIKUMOTO, Y
    HONG, YM
    NISHIDA, T
    NAKAI, S
    MASUI, Y
    HIRAI, Y
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 147 (01) : 315 - 321
  • [47] PHARMACOKINETICS, SAFETY AND IMMUNOMODULATORY EFFECTS OF HUMAN RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST IN HEALTHY HUMANS
    GRANOWTIZ, EV
    PORAT, R
    MIER, JW
    PRIBBLE, JP
    STILES, DM
    BLOEDOW, DC
    CATALANO, MA
    WOLFF, SM
    DINARELLO, CA
    CYTOKINE, 1992, 4 (05) : 353 - 360
  • [48] Comparison study of recombinant human Interleukin-1 receptor antagonist for treating psoriatic and rheumatoid arthritis
    Ischenko, Alexander
    Kleymenova, Irina
    Raymuev, Kiri
    Solovieva, Liudmila
    Antipova, Tatyana
    Simbirtsev, Andrey
    CYTOKINE, 2010, 52 (1-2) : 22 - 22
  • [49] Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist
    Chang, BS
    Reeder, G
    Carpenter, JF
    PHARMACEUTICAL RESEARCH, 1996, 13 (02) : 243 - 249
  • [50] Anakinra, recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in acute myocardial infarction
    Abbate, Antonio
    Sallourn, Fadi N.
    Straino, Stefania
    Das, Anindita
    Dolbrina, Aldo
    Vecile, Elena
    Houser, Jdn-Erk
    Qureshi, Ian Z.
    Vetrovec, George W.
    Badi, Alfonso
    Kukreja, Rakesh N.
    CIRCULATION, 2007, 116 (16) : 271 - 271
12345